Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

BACKGROUND: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ching, Travers, Duncan, Megan E., Newman-Eerkes, Tera, McWhorter, Mollie M. E., Tracy, Jeffrey M., Steen, Michelle S., Brown, Ryan P., Venkatasubbarao, Srivatsa, Akers, Nicholas K., Vignali, Marissa, Moorhead, Martin E., Watson, Drew, Emerson, Ryan O., Mann, Tobias P., Cimler, B. Melina, Swatkowski, Pamela L., Kirsch, Ilan R., Sang, Charles, Robins, Harlan S., Howie, Bryan, Sherwood, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652/
https://www.ncbi.nlm.nih.gov/pubmed/32605647
http://dx.doi.org/10.1186/s12885-020-07077-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652/
https://www.ncbi.nlm.nih.gov/pubmed/32605647
http://dx.doi.org/10.1186/s12885-020-07077-9

Ejemplares similares